All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2020-07-09T14:18:08.000Z

FDA lifts partial hold on the phase II trial of camidanlumab tesirine in patients with R/R Hodgkin lymphoma

Jul 9, 2020
Share:

Bookmark this article

On July 6, 2020, the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on the phase II clinical trial of camidanlumab tesirine in patients with relapsed or refractory (R/R) Hodgkin lymphoma (HL).

Camidanlumab tesirine is an anti-CD25 antibody-drug conjugate which is being evaluated for patients with R/R classical HL (cHL). At the 15th International Conference on Malignant Lymphoma (ICML), the lymphoma hub spoke to Graham Collins, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, who reported the results of the phase I trial (watch the video here).

The pivotal phase II (NCT04052997) multi-center, open-label, single-arm clinical trial is evaluating the safety and efficacy of camidanlumab tesirine in patients with R/R cHL. Patients with R/R cHL who failed three previous lines of therapy including brentuximab vedotin and a checkpoint inhibitor approved for cHL (e.g. nivolumab or pembrolizumab) were eligible for the study. Patients already enrolled in the trial continued to be treated during the partial clinical hold, and now that the hold has been lifted, additional patient enrolment can resume.

The study is expected to support the submission of a Biologics License Application to the FDA.

  1. ADC Therapeutics. ADC Therapeutics announces U.S. Food and Drug Administration has lifted partial clinical hold on pivotal phase 2 clinical trial of camidanlumab tesirine. https://ir.adctherapeutics.com/press-releases/press-release-details/2020/ADC-Therapeutics-Announces-US-Food-and-Drug-Administration-Has-Lifted-Partial-Clinical-Hold-on-Pivotal-Phase-2-Clinical-Trial-of-Camidanlumab-Tesirine/default.aspx. Published Jul 06, 2020. Accessed Jul 08, 2020.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
44 votes - 79 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox